ArticleJournal of nanobiotechnology2017
Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation.
Article in Journal of nanobiotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 165 citations in OpenAlex.
- Integrated Optimization, Genomic Characterization, and Functional Evaluation of Biogenic Selenium Nanoparticles fromInternational journal of molecular sciences · 2026Article
- Umbelliprenin co-formulated with selenium nanoparticles downregulates MMP-2, MMP-9 and ICAM-1 expression in triple-negative breast cancer cells MDA-MB-231.BMC complementary medicine and therapies · 2026Article
- Selenium nanoparticles: Eco-friendly synthesis, biological activities and biomedical applications - A comprehensive review.Materials today. Bio · 2026Review
- A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium-Embedded Mesoporous Silica and Chitosan Nanoparticles.ChemistryOpen · 2026Article
- Phytosynthesis of Selenium Nanoparticles fromAnti-cancer agents in medicinal chemistry · 2026Article
- Recent Advances Towards Selenium Nanoparticles: Synthetic Methods, Functional Mechanisms, and Biological Applications.Foods (Basel, Switzerland) · 2025Review
- Programmed Cell Death in Cancer.MedComm · 2025Review
- Green Synthesis of Chitosan-Coated Selenium Nanoparticles for Paclitaxel Delivery.Nanomaterials (Basel, Switzerland) · 2025Article
- Reactive Oxygen Species: A Double-Edged Sword in the Modulation of Cancer Signaling Pathway Dynamics.Cells · 2025Review
- Co-adjuvant nano particles for hepatocellular carcinoma radiotherapy treatment.Journal of the Egyptian National Cancer Institute · 2025Article
- Exploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials.Cell death discovery · 2025Review
- Synthesis and Biomedical Based Applications of Selenium Nanoparticles: A Comprehensive Review.Indian journal of microbiology · 2025Article
- Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
- The multiple roles of interferon regulatory factor family in health and disease.Signal transduction and targeted therapy · 2024Review
- Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives.Cell death discovery · 2024Review
- Optimization of fermentation parameters to improve the biosynthesis of selenium nanoparticles by Bacillus licheniformis F1 and its comprehensive application.BMC microbiology · 2024Article
- Molecular Mechanisms of the Therapeutic Effect of Selenium Nanoparticles in Hepatocellular Carcinoma.Cells · 2024Review
- Article
- Non-apoptotic regulated cell death mediates reprogramming of the tumour immune microenvironment by macrophages.Journal of cellular and molecular medicine · 2024Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelenium is well documented to inhibit cancer at higher doses; however, the mechanism behind this inhibition varies widely depending on the cell type and selenium species. Previously, we have demonstrated that Bacillus licheniformis JS2 derived biogenic selenium nanoparticles (SeNPs) induce non-apoptotic cell death in prostate adenocarcinoma cell line, PC-3, at a minimal concentration of 2 µg Se/ml, without causing toxicity to the primary cells. However, the mechanism behind its anticancer activity was elusive.
resultsOur results have shown that these SeNPs at a concentration of 2 µg Se/ml were able to induce reactive oxygen species (ROS) mediated necroptosis in PC-3 cells by gaining cellular internalization. Real-time qPCR analysis showed increased expression of necroptosis associated tumor necrotic factor (TNF) and interferon regulatory factor 1 (IRF1). An increased expression of RIP1 protein was also observed at the translational level upon SeNP treatment. Moreover, the cell viability was significantly increased in the presence of necroptosis inhibitor, Necrostatin-1.
conclusionData suggest that our biogenic SeNPs induce cell death in PC-3 cells by the ROS-mediated activation of necroptosis, independent to RIP3 and MLKL, regulated by a RIP1 kinase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.